Meeting Banner
Abstract #4080

Can Diffusion-Weighted Imaging Detect Antihormonal Resistance in Patients with Prostate Cancer Bone Metastases?

Carolin Reischauer 1,2 , Johannes M. Froehlich 1 , Dow-Mu Koh 3 , Ren Patzwahl 4 , Christoph A. Binkert 4 , Sebastian Kos 1 , and Andreas Gutzeit 1,5

1 Institute of Radiology and Nuclear Medicine, Clinical Research Unit, Hirslanden Klinik St. Anna, Lucerne, Switzerland, 2 Institute for Biomedical Engineering, ETH and University Zurich, Zurich, Switzerland, 3 Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom, 4 Department of Radiology, Cantonal Hospital Winterthur, Winterthur, Switzerland, 5 Department of Radiology, Paracelsus Medical University, Salzburg, Austria

Patients suffering from prostate cancer-related bone metastases initially respond well to antihormonal treatment. However, after a period of 2-3 years resistance is usually observed. The present work investigates whether diffusion-weighted imaging permits monitoring this process. It has been previously shown that increased apparent diffusion coefficients (ADCs) are observed at 1 month after commencement of therapy in responders to androgen deprivation. Using ADCs and functional diffusion maps, the present work shows that this initial increase is followed by decreasing ADCs with onset of antihormonal resistance.

This abstract and the presentation materials are available to members only; a login is required.

Join Here